RESOURCE LIBRARY
See below for downloadable clinical practice guidelines, patient education and support materials, and select publications on topics related to help in prevention of secondary CV events with aspirin therapy.
Practice Support Materials
Clinical Practice Guidelines
Clinical practice guidelines continue to recommend aspirin as a top-tier, first-line treatment option.1-8
Secondary Prevention Editorial
Evidence-based editorial discussing the role and benefit-to-risk profile of low-dose aspirin in the prevention of secondary CV events.
Select Publications
ATT Collaboration
The Antithrombotic Trialists’ (ATT) Collaboration meta-analysis of randomized trials of aspirin in the prevention of vascular disease concluded that aspirin can reduce the risk of a second MI by 31%.10
PPI Co-therapy
See how proton pump inhibitor co-therapy with aspirin could help reduce both GI and CV events in patients with CHD, making it a cost-effective approach.11
Adaptable Trial
The Adaptable Study concluded that a daily dose of aspirin 81 mg had efficacy and safety comparable to aspirin 325 mg in secondary CV prevention.12
*Based on a survey of 250 doctors, December 2012.
References: 1. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64(24):e139-228. 2. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-140. doi:10.1016/j.jacc.2012.11.019 3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44-e164. doi:10.1016/j.jacc.2012.07.013 4. Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131(10):927-964. doi:10.1161/CIR.0000000000000182 5. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation. 2016;134(10):e123-e155. doi:10.1161/CIR.0000000000000404 6. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Circulation. 2011;124(4):489-532. doi:10.1161/CIR.0b013e31820d8d78 7. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545-1588. doi:10.1161/01.str.0000442009.06663.48 8. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024 9. Knuuti J, Wijns W, Saraste A, Capodanno D, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425 10. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860. 11. Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther. 2011;34(2):243–251. doi:10.1111/j.1365-2036.2011.04707.x 12. Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;1-10. doi:10.1056/NEJMoa2102137